https://symbiosis.durkancloud.net/news/ 2022-08-10T17:47:35+00:00 https://symbiosis.durkancloud.net/surrozen-announces-key-2022-milestones-for-lead-programs-and-acceleration-of-research-pipeline/ 2022-06-13T21:39:09+00:00 https://symbiosis.durkancloud.net/surrozen-debuts-as-publicly-traded-leader-in-wnt-biology-and-tissue-regeneration/ 2022-06-13T21:39:10+00:00 https://symbiosis.durkancloud.net/will-animal-to-human-organ-transplants-overcome-their-complicated-history/ 2022-06-13T21:39:10+00:00 https://symbiosis.durkancloud.net/ensoma-appoints-cell-and-gene-therapy-pioneer-emile-nuwaysir-ph-d-as-chief-executive-officer/ 2022-06-13T21:39:10+00:00 https://symbiosis.durkancloud.net/ensoma-announces-strategic-collaboration-with-takeda-to-accelerate-next-generation-in-vivo-gene-therapies/ 2022-06-13T21:39:10+00:00 https://symbiosis.durkancloud.net/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer/ 2022-06-13T21:39:10+00:00 https://symbiosis.durkancloud.net/faze-medicines-launches-with-81-million-series-a-financing-to-leverage-new-biology-of-biomolecular-condensates-to-treat-disease/ 2022-06-13T21:39:10+00:00 https://symbiosis.durkancloud.net/tenaya-therapeutics-provides-2022-business-updates/ 2022-06-13T21:39:10+00:00 https://symbiosis.durkancloud.net/tenaya-therapeutics-to-present-preclinical-data-on-its-gene-therapy-programs-at-the-esgct-28th-annual-congress/ 2022-06-13T21:39:10+00:00 https://symbiosis.durkancloud.net/tenaya-therapeutics-announces-closing-of-upsized-initial-public-offering/ 2022-06-13T21:39:10+00:00 https://symbiosis.durkancloud.net/kernal-biologics-presenting-results-at-the-9th-annual-mrna-health-conference/ 2022-06-13T21:39:10+00:00 https://symbiosis.durkancloud.net/kernal-biologics-enters-development-phase-reaching-critical-milestones-for-its-first-mrna-based-cancer-therapeutic-product/ 2022-06-13T21:39:10+00:00 https://symbiosis.durkancloud.net/youve-met-moderna-biontech-and-curevac-now-meet-kernal-bio-the-startup-working-on-mrna-2-0/ 2022-06-13T21:39:10+00:00 https://symbiosis.durkancloud.net/metagenomi-closes-oversubscribed-175m-series-b-financing-to-advance-therapeutic-pipeline-and-expand-novel-gene-editing-platform/ 2022-06-13T21:39:10+00:00 https://symbiosis.durkancloud.net/metagenomi-to-present-preclinical-in-vivo-and-ex-vivo-gene-editing-data-at-the-63rd-american-society-of-hematology-ash-annual-meeting/ 2022-06-13T21:39:10+00:00 https://symbiosis.durkancloud.net/moderna-finally-cracks-into-gene-editing-with-metagenomi-pact-thanks-to-irresistible-data/ 2022-06-13T21:39:10+00:00 https://symbiosis.durkancloud.net/y-combinator-startup-grows-mini-tumors-to-take-the-guesswork-out-of-personalizing-cancer-treatments/ 2022-06-13T21:39:10+00:00 https://symbiosis.durkancloud.net/evommune-in-licenses-three-development-programs-focused-on-treating-inflammatory-conditions-from-dermira-a-wholly-owned-subsidiary-of-eli-lilly-and-company/ 2022-06-13T21:39:10+00:00 https://symbiosis.durkancloud.net/ex-dermira-founders-pick-up-83m-for-evommune-to-advance-programs-in-licensed-from-lillys-dermira/ 2022-06-13T21:39:11+00:00 https://symbiosis.durkancloud.net/cff-supporting-phase-1-2-trial-of-phage-therapy-for-p-aeruginosa-infections/ 2022-06-13T21:39:11+00:00 https://symbiosis.durkancloud.net/biomx-hails-clinical-data-as-first-for-oral-phage-delivery/ 2022-06-13T21:39:11+00:00 https://symbiosis.durkancloud.net/vor33-granted-u-s-fda-fast-track-designation-for-aml/ 2022-06-13T21:39:11+00:00 https://symbiosis.durkancloud.net/vor-to-present-new-platform-and-preclinical-data-at-ash/ 2022-06-13T21:39:11+00:00 https://symbiosis.durkancloud.net/vor-biopharma-announces-collaboration-with-janssen-to-develop-engineered-hematopoietic-stem-cell-transplants-combined-with-a-bi-specific-antibody-therapy-for-acute-myeloid-leukemia-aml/ 2022-06-13T21:39:11+00:00 https://symbiosis.durkancloud.net/vor-to-build-out-state-of-the-art-clinical-manufacturing-facility-capable-of-supporting-multiple-cell-therapy-programs/ 2022-06-13T21:39:11+00:00 https://symbiosis.durkancloud.net/vor-biopharma-closes-over-200m-initial-public-offering-including-full-exercise-of-option-to-purchase-additional-shares/ 2022-06-13T21:39:11+00:00 https://symbiosis.durkancloud.net/vor-announces-fda-clearance-of-ind-application-for-vor33/ 2022-06-13T21:39:11+00:00 https://symbiosis.durkancloud.net/moderna-and-carisma-establish-collaboration-to-develop-in-vivo-engineered-chimeric-antigen-receptor-monocytes-car-m-for-oncology/ 2022-06-13T21:39:11+00:00 https://symbiosis.durkancloud.net/carisma-therapeutics-announces-collaboration-with-merck-to-evaluate-car-macrophages-in-combination-with-keytruda-pembrolizumab-in-a-clinical-study/ 2022-06-13T21:39:11+00:00 https://symbiosis.durkancloud.net/carisma-therapeutics-presents-data-from-phase-i-clinical-trial-of-ct-0508-a-her2-targeted-car-macrophage/ 2022-06-13T21:39:11+00:00 https://symbiosis.durkancloud.net/carisma-therapeutics-announces-u-s-food-and-drug-administration-grants-fast-track-designation-to-ct-0508-for-the-treatment-of-patients-with-solid-tumors/ 2022-06-13T21:39:11+00:00 https://symbiosis.durkancloud.net/carisma-therapeutics-completes-series-b-financing-totaling-59-million/ 2022-06-13T21:39:12+00:00 https://symbiosis.durkancloud.net/clene-nanomedicine-to-present-rescue-als-phase-2-data-in-late-breaking-session-at-32nd-international-symposium-on-als-mnd/ 2022-06-13T21:39:12+00:00 https://symbiosis.durkancloud.net/finch-therapeutics-announces-pricing-of-upsized-initial-public-offering/ 2022-06-13T21:39:12+00:00 https://symbiosis.durkancloud.net/finch-therapeutics-announces-positive-topline-results-from-prism-ext-phase-2-trial-of-cp101-for-prevention-of-recurrent-c-difficile-infection/ 2022-06-13T21:39:12+00:00 https://symbiosis.durkancloud.net/enterome-announces-first-patient-dosed-in-a-phase-1-2-trial-with-second-oncomimics-vaccine-eo2463-in-non-hodgkin-lymphoma/ 2022-06-13T21:39:12+00:00 https://symbiosis.durkancloud.net/siolta-therapeutics-raises-30m-series-b-for-the-prevention-and-treatment-of-allergic-diseases/ 2022-06-13T21:39:12+00:00 https://symbiosis.durkancloud.net/siolta-therapeutics-awarded-nih-grant/ 2022-06-13T21:39:12+00:00 https://symbiosis.durkancloud.net/recursion-announces-transformational-collaboration-with-roche-and-genentech-in-neuroscience-and-oncology-advancing-novel-medicines-to-patients-using-machine-learning-and-high-content-screening-method/ 2022-06-13T21:39:12+00:00 https://symbiosis.durkancloud.net/recursion-and-bayer-expand-fibrosis-collaboration-to-include-inferential-search-capabilities/ 2022-06-13T21:39:12+00:00 https://symbiosis.durkancloud.net/biosplice-therapeutics-closes-120-million-in-equity-financing-to-advance-itsalternative-splicing-platform/ 2022-06-13T21:39:12+00:00 https://symbiosis.durkancloud.net/first-subject-dosed-in-biosplice-therapeutics-phase-1b-clinical-trial-in-oncology/ 2022-06-13T21:39:12+00:00 https://symbiosis.durkancloud.net/dermbiont-announces-acquisition-of-seylanmed-to-expand-its-portfolio-of-targeted-topical-therapeutics-treating-skin-diseases-at-their-root-cause/ 2022-06-13T21:39:12+00:00 https://symbiosis.durkancloud.net/biosplice-therapeutics-closes-120-million-in-equity-financing-to-advance-itsalternative-splicing-platform-2/ 2022-06-13T21:39:13+00:00 https://symbiosis.durkancloud.net/first-subject-dosed-in-biosplice-therapeutics-phase-1b-clinical-trial-in-oncology-2/ 2022-06-13T21:39:13+00:00 https://symbiosis.durkancloud.net/biosplice-licenses-development-and-commercialization-rights-for-lorecivivint-anovel-phase-3-osteoarthritis-drug-candidate-to-haisco-for-the-peoplesrepublic-of-china/ 2022-06-13T21:39:13+00:00 https://symbiosis.durkancloud.net/biosplice-publishes-phase-2b-lorecivivint-analysis-showing-clinically-meaningfulbenefits-to-knee-osteoarthritis-patients/ 2022-06-13T21:39:13+00:00 https://symbiosis.durkancloud.net/biosplice-licenses-rights-to-lorecivivint-a-novel-phase-3-osteoarthritis-drugcandidate-to-samil-for-the-republic-of-korea/ 2022-06-13T21:39:13+00:00 https://symbiosis.durkancloud.net/micronoma-closes-3-5m-convertible-debt-financing-round/ 2022-06-13T21:39:13+00:00 https://symbiosis.durkancloud.net/human-blood-harbors-cell-free-microbial-dna/ 2022-06-13T21:39:13+00:00 https://symbiosis.durkancloud.net/vedanta-biosciences-presents-new-data-from-phase-1-study-of-ve202-its-rationally-defined-consortium-for-the-treatment-of-inflammatory-bowel-disease-at-the-international-human-microbiome-consortium-c/ 2022-06-13T21:39:13+00:00 https://symbiosis.durkancloud.net/vedanta-announces-positive-topline-phase-2-data-for-ve303-in-high-risk-c-difficile-infection-and-exercise-of-23-8-million-option-by-barda/ 2022-06-13T21:39:13+00:00 https://symbiosis.durkancloud.net/vedanta-biosciences-completes-68-million-series-d-financing/ 2022-06-13T21:39:13+00:00 https://symbiosis.durkancloud.net/maat-pharma-announces-positive-interim-engraftment-data-for-oral-formulation-maat033-allowing-early-termination-of-phase-1b-cimon-study/ 2022-06-13T21:39:13+00:00 https://symbiosis.durkancloud.net/maat-pharma-provides-business-objectives-and-expected-milestones-for-2022/ 2022-06-13T21:39:13+00:00 https://symbiosis.durkancloud.net/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting/ 2022-06-13T21:39:13+00:00 https://symbiosis.durkancloud.net/press-releasesmaat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m/ 2022-06-13T21:39:13+00:00 https://symbiosis.durkancloud.net/maat-pharma-and-skyepharma-have-entered-a-partnership-to-establish-the-first-exclusive-microbiome-ecosystem-therapies-cgmp-manufacturing-facility-in-france/ 2022-06-13T21:39:13+00:00 https://symbiosis.durkancloud.net/saliogen-therapeutics-closes-115-million-oversubscribed-series-b-financing-to-advance-gene-codingtm-a-new-category-of-genetic-medicine/ 2022-06-13T21:39:13+00:00 https://symbiosis.durkancloud.net/greenlight-biosciences-and-germains-seed-technology-partner-to-explore-development-of-worlds-first-dsrna-seed-treatment-to-control-pests/ 2022-06-13T21:39:14+00:00 https://symbiosis.durkancloud.net/greenlight-research-recognized-in-four-top-tier-peer-reviewed-papers-in-2021/ 2022-06-13T21:39:14+00:00 https://symbiosis.durkancloud.net/saliogen-therapeutics-appoints-esteemed-industry-veterans-to-executive-advisory-board/ 2022-06-13T21:39:14+00:00 https://symbiosis.durkancloud.net/greenlight-biosciences-and-samsung-biologics-announce-collaboration/ 2022-06-14T01:39:13+00:00 https://symbiosis.durkancloud.net/greenlight-biosciences-begins-trading-today-as-nasdaq-grna-on-the-closing-of-its-business-combination-with-environmental-impact-acquisition-corp/ 2022-06-13T21:39:14+00:00 https://symbiosis.durkancloud.net/nextcure-and-the-national-cancer-institute-announce-preclinical-data-in-journal-of-clinical-investigation/ 2022-07-16T19:58:42+00:00 https://symbiosis.durkancloud.net/nextcure-presented-nc410-data-at-the-extracellular-matrix-ecm-pharmacology-congress-in-europe-on-overcoming-clinical-limitations-to-immunotherapy-through-remodeling-tumor-ecm/ 2022-07-16T19:59:38+00:00 https://symbiosis.durkancloud.net/nextcure-announces-development-of-a-highly-specific-immunohistochemical-diagnostic-for-siglec-15-positive-tumors-as-reported-in-laboratory-investigation/ 2022-07-16T20:00:44+00:00 https://symbiosis.durkancloud.net/nextcure-provides-business-update-and-reports-first-quarter-2022-financial-results/ 2022-07-16T20:01:45+00:00 https://symbiosis.durkancloud.net/tcr%c2%b2-therapeutics-announces-positive-interim-results-from-ongoing-phase-1-2-trial-of-gavo-cel-for-treatment-refractory-mesothelin-expressing-solid-tumors/ 2022-07-16T20:02:45+00:00 https://symbiosis.durkancloud.net/tcr%c2%b2-therapeutics-presents-preclinical-data-on-il-15-enhanced-trucs-at-aacr-virtual-special-conference-on-tumor-immunology-immunotherapy/ 2022-07-16T20:04:06+00:00 https://symbiosis.durkancloud.net/tcr%c2%b2-therapeutics-announces-expansion-of-u-s-manufacturing-capacity/ 2022-07-16T20:05:11+00:00 https://symbiosis.durkancloud.net/tcr%c2%b2-therapeutics-announces-2022-strategic-priorities-and-anticipated-milestones/ 2022-07-16T20:06:10+00:00 https://symbiosis.durkancloud.net/tcr%c2%b2-therapeutics-reports-first-quarter-2022-financial-results-and-provides-corporate-update/ 2022-07-16T20:08:15+00:00 https://symbiosis.durkancloud.net/vor-bio-reports-first-quarter-2022-financial-results-and-provides-company-update/ 2022-07-16T20:08:58+00:00 https://symbiosis.durkancloud.net/vor-bio-successfully-demonstrates-multiplex-editing-of-hematopoietic-stem-cells-for-next-generation-aml-treatment-presented-at-eha/ 2022-07-16T20:09:58+00:00 https://symbiosis.durkancloud.net/vedanta-biosciences-completes-68-million-series-d-financing-2/ 2022-07-16T20:10:47+00:00 https://symbiosis.durkancloud.net/vedanta-announces-positive-topline-phase-2-data-for-ve303-in-high-risk-c-difficile-infection-and-exercise-of-23-8-million-option-by-barda-2/ 2022-07-16T20:11:52+00:00 https://symbiosis.durkancloud.net/vedanta-biosciences-publishes-phase-1a-1b-results-for-lead-program-ve303-in-cell-host-microbe-and-highlights-planned-presentations-of-phase-2-ve303-results/ 2022-07-16T20:12:56+00:00 https://symbiosis.durkancloud.net/vedanta-presents-data-from-multiple-studies-at-digestive-disease-week-2022-annual-meeting/ 2022-07-16T20:13:55+00:00 https://symbiosis.durkancloud.net/vedanta-unveils-state-of-the-art-manufacturing-facility-to-provide-clinical-and-commercial-supply-of-oral-therapies-based-on-defined-bacterial-consortia/ 2022-07-16T20:15:05+00:00 https://symbiosis.durkancloud.net/tenaya-therapeutics-to-present-preclinical-data-on-gene-therapy-programs-and-platform-capabilities-at-the-american-society-of-gene-and-cell-therapy-25th-annual-meeting/ 2022-07-16T20:15:56+00:00 https://symbiosis.durkancloud.net/tenaya-therapeutics-reports-first-quarter-2022-financial-results-and-provides-business-update/ 2022-07-16T20:16:53+00:00 https://symbiosis.durkancloud.net/tenaya-therapeutics-launches-operations-of-new-genetic-medicines-manufacturing-center-to-support-the-development-of-potentially-first-in-class-cardiovascular-therapeutics/ 2022-07-16T20:17:32+00:00 https://symbiosis.durkancloud.net/surrozen-reports-first-quarter-2022-financial-results/ 2022-07-16T20:19:22+00:00 https://symbiosis.durkancloud.net/surrozen-publishes-article-in-cellular-and-molecular-gastroenterology-and-hepatology-demonstrating-that-szn-1326-a-selective-wnt-mimetic-stimulated-robust-colon-epithelial-regeneration-and-ameliorat/ 2022-07-16T20:20:08+00:00 https://symbiosis.durkancloud.net/surrozen-initiates-dosing-in-phase-1-clinical-trial-of-szn-1326-for-moderate-to-severe-ulcerative-colitis/ 2022-07-16T20:21:04+00:00 https://symbiosis.durkancloud.net/surrozen-presents-data-on-lead-therapeutic-candidates-at-digestive-disease-week-ddw/ 2022-07-16T20:22:29+00:00 https://symbiosis.durkancloud.net/surrozen-initiates-dosing-in-phase-1-clinical-trial-of-szn-043-for-severe-alcoholic-hepatitis/ 2022-07-16T20:23:29+00:00 https://symbiosis.durkancloud.net/recursion-announces-enrollment-of-first-patient-in-phase-2-trial-for-the-treatment-of-cerebral-cavernous-malformation/ 2022-07-16T20:24:27+00:00 https://symbiosis.durkancloud.net/recursion-is-granted-fast-track-designation-for-rec-4881-for-the-potential-treatment-of-familial-adenomatous-polyposis/ 2022-07-16T20:25:06+00:00 https://symbiosis.durkancloud.net/recursion-provides-business-updates-and-reports-first-quarter-2022-financial-results/ 2022-07-16T20:25:56+00:00 https://symbiosis.durkancloud.net/recursion-announces-initiation-of-phase-2-3-trial-for-the-treatment-of-nf2-mutated-meningiomas-at-childrens-tumor-foundation-nf-conference/ 2022-07-16T20:26:45+00:00 https://symbiosis.durkancloud.net/neurona-therapeutics-dosed-initial-subject-in-first-clinical-trial-of-regenerative-human-cell-therapy/ 2022-07-16T20:27:45+00:00 https://symbiosis.durkancloud.net/maat-pharma-publishes-its-cash-position-and-sales-for-the-first-quarter-of-2022/ 2022-07-16T20:28:51+00:00 https://symbiosis.durkancloud.net/metagenomi-presents-new-preclinical-data-at-asgct-on-proprietary-highly-efficient-crispr-gene-editing-systems-and-a-novel-family-of-crispr-associated-transposases-casts/ 2022-07-16T20:29:33+00:00 https://symbiosis.durkancloud.net/affini-t-therapeutics-metagenomi-announce-next-generation-gene-editing-partnership-to-advance-cell-therapies-for-solid-tumor-patients/ 2022-07-16T20:30:18+00:00 https://symbiosis.durkancloud.net/maat-pharma-confirms-positive-results-from-completed-phase-1b-cimon-study-evaluating-maat033-in-blood-cancer-patients/ 2022-07-16T20:31:23+00:00 https://symbiosis.durkancloud.net/enterome-presents-proof-of-concept-immune-response-data-and-first-clinical-data-from-phase-1-2-trial-with-eo2401-a-first-in-class-oncomimics-therapeutic-cancer-vaccine-for-adrenocortical-car/ 2022-07-16T20:33:00+00:00 https://symbiosis.durkancloud.net/enterome-presents-proof-of-concept-immune-response-data-and-first-clinical-data-from-phase-1-2-trial-with-eo2401-a-first-in-class-oncomimics-therapeutic-cancer-vaccine-for-glioblastoma-at-a/ 2022-07-16T20:33:44+00:00 https://symbiosis.durkancloud.net/egenesis-appoints-eliezer-katz-m-d-facs-as-chief-medical-officer/ 2022-07-16T20:34:53+00:00 https://symbiosis.durkancloud.net/egenesis-promotes-michael-curtis-ph-d-to-chief-executive-officer/ 2022-07-16T20:35:36+00:00 https://symbiosis.durkancloud.net/clene-reports-first-quarter-2022-financial-results-and-recent-operating-highlights/ 2022-07-16T20:36:22+00:00 https://symbiosis.durkancloud.net/biomx-reports-first-quarter-2022-financial-results-and-provides-business-update/ 2022-07-16T20:38:26+00:00 https://symbiosis.durkancloud.net/biomx-announces-dosing-of-the-first-two-patients-in-phase-1b-2a-study-of-bx004-for-treatment-of-chronic-respiratory-infections-in-patients-with-cystic-fibrosis/ 2022-07-16T20:39:09+00:00 https://symbiosis.durkancloud.net/boehringer-expands-biomx-ibd-biomarker-collab-shutters-crohns-trial/ 2022-07-16T20:40:08+00:00